Merck & Company (MRK)

$79.06 -0.23 (-0.29%)
Market Cap 199.10B
Revenue (ttm) 64.17B
Net Income (ttm) 17.12B
EPS (ttm) N/A
PE Ratio 10.05
Forward PE 8.89
Profit Margin 26.68%
Debt to Equity Ratio 0.69
Volume 34,052,200
Avg Vol 15,808,718
Day's Range N/A - N/A
Shares Out 2.51B
Stochastic %K 37%
Beta 0.38
Analysts Strong Sell
Price Target $103.68

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
GemsBot
GemsBot Jun. 21 at 11:54 AM
7 of 11 $MMM $MRK $MSFT For swing trades the daily timeframe is used. SSI also works well with 30 minutes timeframe for intraday trades and 5 minutes for scalp trades, but you need to install the SSI on your computer for those … see 8/11
0 · Reply
BachelorBull
BachelorBull Jun. 20 at 4:24 PM
$MRK MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!
0 · Reply
BachelorBull
BachelorBull Jun. 20 at 2:39 PM
$MRK Comeover to $NCNA and join the Keytruda Cancer Treatment profile with 40% increase of effectiveness
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 20 at 12:22 PM
Value alert: $MRK ranks in our AI's top 30 value picks from 5700+ analyzed stocks. Trading at 11.5 P/E (35% below sector) with 4.14% dividend yield. Q1 showed 35.7% net income growth, improved debt ratio (0.72), and 19.86x interest coverage. Defensive beta (0.44) + Keytruda patents through 2028 create rare stability-growth combo. Full analysis available at aipha.io - no signup required.
0 · Reply
Tat2doc
Tat2doc Jun. 20 at 11:43 AM
$LLY $GSK $MRK $ABBV $PFE it’s a big pharma Friday! 🚀 Bunker bust my butt! Money talks and bs walks!
0 · Reply
FinJay
FinJay Jun. 20 at 4:19 AM
$MRK https://youtu.be/Ps8OqdQFpfs
0 · Reply
NYC100
NYC100 Jun. 19 at 10:30 PM
$BMY $GILD $MRK $NUVB $PFE it has happened to me before I sold a stock because this seeking Alpha wrote a bad article and after I sold it, the stock went up 100% or more 😂😂
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 9:54 PM
Merck ($MRK) quietly strengthens its foothold in the $15B HER2-low cancer race. While ENHERTU dominates now, their ifinatamab deruxtecan/MK-2400 ADC shows promise in Phase III. With the HER2-low market growing at 9.4% CAGR, today's pipeline depth could challenge AstraZeneca/Daiichi's lead. Watch the ADC arms race heat up. https://www.prnewswire.com/news-releases/her2-low-cancers-market-set-to-register-immense-growth-at-a-cagr-of-9-4-during-the-study-period-20202034--delveinsight-302486020.html
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 9:33 PM
Merck ($MRK) expands its oncology ambitions with Daiichi Sankyo partnership on MK-6070 for small cell lung cancer. As R&D spend surges 44% YoY, the market bets on ADC therapies to diversify beyond Keytruda. With DLL3-targeted pipelines heating up, big pharma's chess game in precision oncology intensifies. https://www.prnewswire.com/news-releases/delta-like-ligand-3-targeted-therapies-market-is-predicted-to-heat-up-during-the-forecast-period-20252034-across-7mm-owing-to-a-robust-pipeline--delveinsight-302486027.html
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 19 at 2:52 PM
$NUVB I read thru the seeking alpha article after @BioCapitalist99 alerted me - it’s hogwash. Phase 4 studies are often required, and the first one for pediatric cancer is good news on multiple fronts. There aren’t many children with ROS1+ NSCLC (thank God), but that trial should extend Ibtrozi’s patents. They also didn’t check LinkedIn. The sales force at Nuvation is great - many are friends from my Celgene days prior to our acquisition by $BMY . Quite a few of them were at Medivation & Immunomedics prior to their acquisitions as well (by $PFE & $GILD , respectively). I currently own a little over 11K shares and will likely buy more if it stays this cheap. Hung won’t sell this for $14B like Medivation, but Ibtrozi is worth a couple of billion to a large pharma buyer - most likely not $MRK (although they need to be cutting deals left and right before Keytruda faces LOE. I’m a Nuvation bull 🐂 And this Seeking Alpha article is 🐂 💩 Good Luck to my fellow Bulls! ☘️
1 · Reply
Latest News on MRK
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports

Jun 18, 2025, 1:05 PM EDT - 3 days ago

RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports

PFE SNY

RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury

Jun 18, 2025, 1:01 PM EDT - 3 days ago

RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury

PFE SNY

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Jun 18, 2025, 7:39 AM EDT - 3 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

PFE XRAY

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Jun 18, 2025, 7:00 AM EDT - 3 days ago

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Jun 17, 2025, 10:00 AM EDT - 4 days ago

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

ABBV AMGN JNJ PFE

2 Wonderful Dividends Practically Giving Themselves Away

Jun 16, 2025, 8:30 AM EDT - 5 days ago

2 Wonderful Dividends Practically Giving Themselves Away

FRT

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

Jun 13, 2025, 9:40 AM EDT - 8 days ago

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

Jun 13, 2025, 6:45 AM EDT - 8 days ago

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

Jun 12, 2025, 4:45 PM EDT - 8 days ago

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

5 stocks to consider right now amid volatility and uncertainty: Portfolio manager

Jun 12, 2025, 4:07 PM EDT - 8 days ago

5 stocks to consider right now amid volatility and uncertainty: Portfolio manager

CIVI TGT UPS WHR

Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine

Jun 12, 2025, 11:24 AM EDT - 9 days ago

Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine

Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025

Jun 12, 2025, 8:30 AM EDT - 9 days ago

Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

Jun 12, 2025, 6:45 AM EDT - 9 days ago

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

Merck: Best Case For Option Collars We'll Ever See

Jun 10, 2025, 5:04 PM EDT - 10 days ago

Merck: Best Case For Option Collars We'll Ever See

Drug pricing reform talks with US government lack clarity, industry executives say

Jun 10, 2025, 2:03 PM EDT - 10 days ago

Drug pricing reform talks with US government lack clarity, industry executives say

LLY

Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 10, 2025, 12:56 PM EDT - 11 days ago

Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

Jun 10, 2025, 12:47 PM EDT - 11 days ago

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

ACI BMY CMCSA COP CVS CVX EPD

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

Jun 10, 2025, 11:50 AM EDT - 11 days ago

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

BNTX MRNA PFE

Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee

Jun 10, 2025, 10:49 AM EDT - 11 days ago

Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee

The Highest-Quality Dividend Contenders By Quality Scores

Jun 10, 2025, 9:00 AM EDT - 11 days ago

The Highest-Quality Dividend Contenders By Quality Scores

AAPL ABT ACN AMP AON CASS CMCSA

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca

Jun 9, 2025, 3:30 PM EDT - 11 days ago

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca

US FDA approves Merck's RSV antibody for infants

Jun 9, 2025, 3:16 PM EDT - 11 days ago

US FDA approves Merck's RSV antibody for infants

U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season

Jun 9, 2025, 3:11 PM EDT - 11 days ago

U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Jun 9, 2025, 9:19 AM EDT - 12 days ago

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

GSK PFE

Merck's cholesterol drug meets main goal in late-stage studies

Jun 9, 2025, 6:59 AM EDT - 12 days ago

Merck's cholesterol drug meets main goal in late-stage studies

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

Jun 9, 2025, 6:45 AM EDT - 12 days ago

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 10% (June 2025)

Jun 7, 2025, 8:00 AM EDT - 14 days ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 10% (June 2025)

ADP AES AMH ARCC ARE BTI CSL

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Jun 5, 2025, 1:56 PM EDT - 15 days ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

ALVO RDY

Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 4, 2025, 6:45 AM EDT - 17 days ago

Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Jun 3, 2025, 3:34 PM EDT - 17 days ago

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

AZN GILD PFE AMGN BMY BNTX

Is Merck Stock About To Crash?

Jun 3, 2025, 8:25 AM EDT - 18 days ago

Is Merck Stock About To Crash?

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Jun 2, 2025, 5:08 PM EDT - 18 days ago

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

MLTX

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jun 2, 2025, 2:51 PM EDT - 18 days ago

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

BMY BNTX BPMC SNY

Merck Stock's Ticking Keytruda Time Bomb

Jun 2, 2025, 9:20 AM EDT - 19 days ago

Merck Stock's Ticking Keytruda Time Bomb

2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away

Jun 2, 2025, 7:30 AM EDT - 19 days ago

2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away

CVE

Top 10 High-Yield Dividend Stocks

Jun 1, 2025, 11:44 PM EDT - 19 days ago

Top 10 High-Yield Dividend Stocks

CMCSA EOG NEE PEP PNC QSR SPY

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

May 31, 2025, 8:13 AM EDT - 21 days ago

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

GILD

KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)

May 31, 2025, 8:00 AM EDT - 21 days ago

KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)

Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting

May 30, 2025, 12:23 PM EDT - 22 days ago

Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting

AMGN GSK PFE

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations

May 30, 2025, 8:05 AM EDT - 22 days ago

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations

Merck's Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial

May 30, 2025, 8:00 AM EDT - 22 days ago

Merck's Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial

Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

May 29, 2025, 7:42 PM EDT - 22 days ago

Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Merck, Daiichi withdraw US application for 'guided missile' cancer drug

May 29, 2025, 7:14 AM EDT - 23 days ago

Merck, Daiichi withdraw US application for 'guided missile' cancer drug

Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

May 29, 2025, 7:00 AM EDT - 23 days ago

Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Merck Proves Why It's Still A Top Pharma Pick

May 27, 2025, 3:46 PM EDT - 24 days ago

Merck Proves Why It's Still A Top Pharma Pick

Merck Announces Third-Quarter 2025 Dividend

May 27, 2025, 1:24 PM EDT - 25 days ago

Merck Announces Third-Quarter 2025 Dividend

Should You Buy MRK Stock At $80?

May 26, 2025, 12:00 PM EDT - 26 days ago

Should You Buy MRK Stock At $80?

Merck: Defensive Yield Meets Long-Term Optionality

May 23, 2025, 11:05 AM EDT - 4 weeks ago

Merck: Defensive Yield Meets Long-Term Optionality

Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025

May 22, 2025, 5:43 PM EDT - 4 weeks ago

Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025

Merck: Undervalued In Light Of Key Risks

May 22, 2025, 12:30 PM EDT - 4 weeks ago

Merck: Undervalued In Light Of Key Risks

GemsBot
GemsBot Jun. 21 at 11:54 AM
7 of 11 $MMM $MRK $MSFT For swing trades the daily timeframe is used. SSI also works well with 30 minutes timeframe for intraday trades and 5 minutes for scalp trades, but you need to install the SSI on your computer for those … see 8/11
0 · Reply
BachelorBull
BachelorBull Jun. 20 at 4:24 PM
$MRK MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!MERCK PLEASE BUY THE NUC 7738!!!
0 · Reply
BachelorBull
BachelorBull Jun. 20 at 2:39 PM
$MRK Comeover to $NCNA and join the Keytruda Cancer Treatment profile with 40% increase of effectiveness
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 20 at 12:22 PM
Value alert: $MRK ranks in our AI's top 30 value picks from 5700+ analyzed stocks. Trading at 11.5 P/E (35% below sector) with 4.14% dividend yield. Q1 showed 35.7% net income growth, improved debt ratio (0.72), and 19.86x interest coverage. Defensive beta (0.44) + Keytruda patents through 2028 create rare stability-growth combo. Full analysis available at aipha.io - no signup required.
0 · Reply
Tat2doc
Tat2doc Jun. 20 at 11:43 AM
$LLY $GSK $MRK $ABBV $PFE it’s a big pharma Friday! 🚀 Bunker bust my butt! Money talks and bs walks!
0 · Reply
FinJay
FinJay Jun. 20 at 4:19 AM
$MRK https://youtu.be/Ps8OqdQFpfs
0 · Reply
NYC100
NYC100 Jun. 19 at 10:30 PM
$BMY $GILD $MRK $NUVB $PFE it has happened to me before I sold a stock because this seeking Alpha wrote a bad article and after I sold it, the stock went up 100% or more 😂😂
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 9:54 PM
Merck ($MRK) quietly strengthens its foothold in the $15B HER2-low cancer race. While ENHERTU dominates now, their ifinatamab deruxtecan/MK-2400 ADC shows promise in Phase III. With the HER2-low market growing at 9.4% CAGR, today's pipeline depth could challenge AstraZeneca/Daiichi's lead. Watch the ADC arms race heat up. https://www.prnewswire.com/news-releases/her2-low-cancers-market-set-to-register-immense-growth-at-a-cagr-of-9-4-during-the-study-period-20202034--delveinsight-302486020.html
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 9:33 PM
Merck ($MRK) expands its oncology ambitions with Daiichi Sankyo partnership on MK-6070 for small cell lung cancer. As R&D spend surges 44% YoY, the market bets on ADC therapies to diversify beyond Keytruda. With DLL3-targeted pipelines heating up, big pharma's chess game in precision oncology intensifies. https://www.prnewswire.com/news-releases/delta-like-ligand-3-targeted-therapies-market-is-predicted-to-heat-up-during-the-forecast-period-20252034-across-7mm-owing-to-a-robust-pipeline--delveinsight-302486027.html
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 19 at 2:52 PM
$NUVB I read thru the seeking alpha article after @BioCapitalist99 alerted me - it’s hogwash. Phase 4 studies are often required, and the first one for pediatric cancer is good news on multiple fronts. There aren’t many children with ROS1+ NSCLC (thank God), but that trial should extend Ibtrozi’s patents. They also didn’t check LinkedIn. The sales force at Nuvation is great - many are friends from my Celgene days prior to our acquisition by $BMY . Quite a few of them were at Medivation & Immunomedics prior to their acquisitions as well (by $PFE & $GILD , respectively). I currently own a little over 11K shares and will likely buy more if it stays this cheap. Hung won’t sell this for $14B like Medivation, but Ibtrozi is worth a couple of billion to a large pharma buyer - most likely not $MRK (although they need to be cutting deals left and right before Keytruda faces LOE. I’m a Nuvation bull 🐂 And this Seeking Alpha article is 🐂 💩 Good Luck to my fellow Bulls! ☘️
1 · Reply
Jimmybelanger3
Jimmybelanger3 Jun. 19 at 5:40 AM
$MRK great buy
0 · Reply
jwan305
jwan305 Jun. 19 at 2:04 AM
$MRK I'm surprised this has stayed this low for this long.. I have cash on hand to buy a dip.. I'm In at $84.81 but I want to buy a dip.. trading sideways for 2 weeks Is boring.. guess just got to be patient with them. till then, dividends. enjoy. easy double though.
0 · Reply
CaesarZane
CaesarZane Jun. 18 at 11:04 PM
$MS $MRK $GS - undervalued stocks 📈 Full Analysis: https://youtu.be/UzROILun8cQ
0 · Reply
Bullishbruk
Bullishbruk Jun. 18 at 9:22 PM
$IBRX just buy these cheap shares on $MRK accounts…no one else is about to lose big time except MRK #keytuda VS #Anktiva it is obvious
0 · Reply
swingingtech
swingingtech Jun. 18 at 8:35 PM
$FIP $MRK $PENN https://wallstreetwaves.com/highlighting-wednesdays-significant-options-activity-fip-mrk-penn/
0 · Reply
NYMACOAZ
NYMACOAZ Jun. 18 at 4:26 PM
$MRK this is not a day trader stock! Buy, hold, and reap the rewards of patience I see $150 in under 12 months. Plus, the dividends are sweet.
1 · Reply
swimmy
swimmy Jun. 18 at 3:43 PM
$MRK massive reversal in the making, after latest downgrade.
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jun. 18 at 3:30 PM
$MRK interesting... citi cuts Merck today to 84 pt... 10:53 AM EDT, June 18, 2025 (Benzinga Newswire) CORRECTION: Citigroup analyst Geoff Meacham downgrades Merck & Co (NYSE:MRK) from Buy to Neutral and lowers the price target from $115 to $84.
0 · Reply
mickeyp_
mickeyp_ Jun. 18 at 3:30 PM
$MRK moving
0 · Reply
swingingtech
swingingtech Jun. 18 at 2:40 PM
$JPM $MRK $MSFT $GS https://wallstreetwaves.com/key-contributors-to-dow-mrk-and-jpm/
0 · Reply
JohnnyBrewno
JohnnyBrewno Jun. 18 at 2:30 PM
$NCNA $PFE $MRK $MRNA
0 · Reply
igOPTIONSKING_
igOPTIONSKING_ Jun. 18 at 2:26 PM
$MRK Caught the gap down. 100% on 78 strike puts
0 · Reply